Vertex Pharmaceuticals ( VRTX 2.53%) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs ...

Journavx is the first and only approved non-opioid oral painkiller and the first new class of pain medicine approved in more ...

Despite high demand for an option like Journavx, doctors fear the drug’s price could be a hangup for insurers and limit ...

Each year, about 125 million opioid prescriptions are written for Americans with pain caused by broken bones, burns, ...

Will people with acute pain want a new painkiller whose list price is $15.50 a pill when a generic prescription drug is at ...

The FDA has approved a new type of painkiller that doesn't come with the risks of addiction and overdose associated with ...

Vertex also has the ambition to extend the use of suzetrigine into the chronic pain setting, but the results of a phase 2 trial involving patients with lumbosacral radiculopathy, a form of chronic ...

The approval culminates a long, painstaking development process, with Vertex emerging successful after several other companies abandoned their efforts to create a treatment using a similar ...

Financial giants have made a conspicuous bearish move on Vertex Pharmaceuticals. Our analysis of options history for Vertex ...

Analyst Salveen Richter of Goldman Sachs maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), reducing the price target ...